In vitro activity and mechanism of action of A21978C1, a novel cyclic lipopeptide antibiotic
about
Cyclic lipodepsipeptides: a new class of antibacterial agents in the battle against resistant bacteriaComparative in vitro antibiotic resistance of surface-colonizing coagulase-negative staphylococci.In vitro activity of SK&F 104662, a new glycopeptide antibiotic.Combination therapy with iron chelation and vancomycin in treating murine staphylococcemia.Resistance studies with daptomycinDaptomycin-mediated reorganization of membrane architecture causes mislocalization of essential cell division proteinsNatural products to drugs: daptomycin and related lipopeptide antibiotics.Additional routes to Staphylococcus aureus daptomycin resistance as revealed by comparative genome sequencing, transcriptional profiling, and phenotypic studies.Daptomycin resistance mechanisms in clinically derived Staphylococcus aureus strains assessed by a combined transcriptomics and proteomics approachActivities of daptomycin and teicoplanin against Staphylococcus haemolyticus and Staphylococcus epidermidis, including evaluation of susceptibility testing recommendationsComparative evaluation of daptomycin (LY146032) and vancomycin in the treatment of experimental methicillin-resistant Staphylococcus aureus osteomyelitis in rabbits.In vitro susceptibility studies of vancomycin-resistant Enterococcus faecalisEffects of reduced cation supplement recommendations (National Committee for Clinical Laboratory Standards) on daptomycin antistaphylococcal activityEffect of calcium on in vitro activity of LY146032 against Clostridium difficile.Antimicrobial activity and spectrum of LY146032, a lipopeptide antibiotic, including susceptibility testing recommendations.Bactericidal activity of deptomycin (LY146032) compared with those of ciprofloxacin, vancomycin, and ampicillin against enterococci as determined by kill-kinetic studiesActivity of LY146032 compared with that of methicillin, cefazolin, cefamandole, cefuroxime, ciprofloxacin, and vancomycin against staphylococci as determined by kill-kinetic studies.Activity of LY146032 against Enterococci with and without high-level aminoglycoside resistance, including two penicillinase-producing strainsIn vitro activity of LY146032 against staphylococci, streptococci, and enterococci[Resistance to "last resort" antibiotics in Gram-positive cocci: The post-vancomycin era].Failure of routine susceptibility tests to detect imipenem resistance among strains of methicillin-resistant Staphylococcus aureus.Daptomycin disrupts membrane potential in growing Staphylococcus aureus.Susceptibility testing of clinical isolates of Enterococcus faecium and Enterococcus faecalis.Therapeutic update on glycopeptide and lipopeptide antibiotics.Efficacy of daptomycin in experimental endocarditis due to methicillin-resistant Staphylococcus aureus.Lipoteichoic acid as a new target for activity of antibiotics: mode of action of daptomycin (LY146032)Comparison of cefazolin, cefamandole, vancomycin, and LY146032 for prophylaxis of experimental Staphylococcus epidermidis endocarditis.LY146032, alone and in combination with gentamicin, for the treatment of enterococcal pyelonephritis in the rat model.Early stages of in vitro killing curve of LY146032 and vancomycin for Staphylococcus aureus.In vitro synergism between daptomycin and fosfomycin against Enterococcus faecalis isolates with high-level gentamicin resistance.In vitro activity of LY146032, a new lipopeptide antibiotic, against gram-positive cocci.In vitro activity of a new cyclic lipopeptide antibiotic, LY146032, against gram-positive clinical bacteria.Inhibition of peptidoglycan biosynthesis in gram-positive bacteria by LY146032In vitro and in vivo activity of LY 146032, a new cyclic lipopeptide antibiotic.Pharmacodynamics of daptomycin and vancomycin on Enterococcus faecalis and Staphylococcus aureus demonstrated by studies of initial killing and postantibiotic effect and influence of Ca2+ and albumin on these drugs.Inhibition of membrane potential-dependent amino acid transport by daptomycin.Lipoteichoic acid and lipids in the membrane of Staphylococcus aureus.Self-Assembly of the Cyclic Lipopeptide Daptomycin: Spherical Micelle Formation Does Not Depend on the Presence of Calcium Chloride.The lipopeptide antibiotic Friulimicin B inhibits cell wall biosynthesis through complex formation with bactoprenol phosphate.Influence of Ca(2+) ions on the activity of lantibiotics containing a mersacidin-like lipid II binding motif
P2860
Q26863225-EFF108D2-AF93-4FFE-9791-2385EF8B0173Q33741953-EDAD849C-7923-48C4-97A2-B39DA8571E18Q33742958-90C596C6-6505-49C9-B164-80D30E3641A1Q33875365-FF1B091A-D7B2-42F1-928E-5C78AC2C9593Q33982318-6B710604-D6E0-40FC-9678-F1E673D63851Q34278802-D9773B09-B756-4F27-8BE9-562275FDD6A2Q34470713-886CA138-C318-4CAE-AFD1-E7838E3B1AC8Q34648042-4F5C4DAE-6A39-4FF8-A9AE-364CDB7451E7Q35096905-994F5CB1-9C1C-42A9-BE94-F1FD82AC3BBFQ35329160-BE32B62D-9A5D-4054-823D-3040441E7DBEQ35332478-84D3E59D-4ECA-42ED-B74B-383A0BC8A79DQ35350299-B770A9BF-603E-473A-BE2F-13D4D12DCEC8Q35352499-12F28286-D837-44AF-8EAE-D16F63D8FB7BQ35537987-0BC50930-BE1E-40E1-A1C3-668258674686Q35539120-D767C0A9-DBAC-42BA-B452-D37B27F88131Q35540772-4FED9E1B-05C3-4CA9-9927-6DC81A1D524AQ35541070-2A111015-9F62-455C-BA85-EDB173D2FCC8Q35543452-3FB4A935-43A7-4AC7-9E11-6D89486E624AQ35575774-2F5E4C8B-FEB6-4DA0-BA6B-9C31D2B7D530Q35619094-DCA9E8D3-34A1-4009-8175-4DBEAB2117AEQ36754338-A4CD339B-C01B-4155-99D8-D04C6D986A25Q36756893-D861FCF3-793A-4AF2-9367-BD76475800DDQ37114177-D9F0252E-02BA-45CE-B613-1F2DEDA40CFAQ39291062-E94A4600-B78B-48BA-AC56-1105D0C41EFCQ39746366-AA4E58F0-A254-4F66-B54F-76CFE3722C38Q39816283-1F079DBB-61AF-467A-B8A3-9BCD5A224F6EQ39817484-DF2523F0-A835-4825-BB52-A1ABCC6C617AQ39817510-2CD49A27-84E0-43EE-9AA9-8F2B62B6AEB1Q39817922-930EEE72-6B7C-4BC1-B8CB-BA88F9894921Q39818976-68D2E83F-950E-4E94-BC7B-4BC928F17954Q39827756-5BCDA57E-D992-466E-960C-509E641F235DQ39827877-49955E33-803B-47E5-9F9B-6C07820A7E5AQ39828406-8C186042-0122-45B2-A77A-049F995EB191Q39834787-B31FD5D5-5405-4ECC-96CE-119F72751D77Q40087244-E1587A7A-FCF7-4110-BB0A-9699C7047AD7Q40088405-4493DCFD-C9E5-48F2-B88D-8B057EDB6CD2Q40637175-F8FBADE4-A236-4774-B9DE-B2C3125A2C5BQ40729383-5776A086-F1AD-49BE-8100-60B35EC83C0BQ42140912-767AAE9C-81C0-4A5E-AF64-55A5A608AFA2Q42178399-51BB79AF-7DE1-4A2F-9772-423FDC55071E
P2860
In vitro activity and mechanism of action of A21978C1, a novel cyclic lipopeptide antibiotic
description
1985 nî lūn-bûn
@nan
1985年の論文
@ja
1985年論文
@yue
1985年論文
@zh-hant
1985年論文
@zh-hk
1985年論文
@zh-mo
1985年論文
@zh-tw
1985年论文
@wuu
1985年论文
@zh
1985年论文
@zh-cn
name
In vitro activity and mechanis ...... cyclic lipopeptide antibiotic
@ast
In vitro activity and mechanis ...... cyclic lipopeptide antibiotic
@en
type
label
In vitro activity and mechanis ...... cyclic lipopeptide antibiotic
@ast
In vitro activity and mechanis ...... cyclic lipopeptide antibiotic
@en
prefLabel
In vitro activity and mechanis ...... cyclic lipopeptide antibiotic
@ast
In vitro activity and mechanis ...... cyclic lipopeptide antibiotic
@en
P2093
P2860
P356
P1476
In vitro activity and mechanis ...... cyclic lipopeptide antibiotic
@en
P2093
Eliopoulos GM
Moellering RC Jr
P2860
P304
P356
10.1128/AAC.27.3.357
P407
P577
1985-03-01T00:00:00Z